EGFR and non-small cell lung carcinoma: It is well known that osimertinib has showed superior efficacy for treatment of EGFR-mutated advanced NSCLC compared with first-generation EGFR-TKIs, as demonstrated by significantly improving prognosis without increasing toxic side effects and reducing the risk of CNS metastasis (Ramalingam et al., 2020).